Literature DB >> 24253377

Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma.

Hiroyuki Okazaki1, Naoya Matsunaga, Takashi Fujioka, Fumiyasu Okazaki, Yui Akagawa, Yuuya Tsurudome, Mayumi Ono, Michihiko Kuwano, Satoru Koyanagi, Shigehiro Ohdo.   

Abstract

Circadian clock systems regulate many biologic functions, including cell division and hormone secretion in mammals. In this study, we explored the effects of circadian control on the pivot cell growth regulatory mTOR, the activity of which is deregulated in tumor cells compared with normal cells. Specifically, we investigated whether the antitumor effect of an mTOR inhibitor could be improved by changing its dosing schedule in RenCa tumor-bearing mice. Active, phosphorylated mTOR displayed a 24-hour rhythm, and levels of total mTOR protein (but not mRNA) also showed a circadian rhythm in RenCa tumor masses. Through investigations of the oscillation mechanism for mTOR expression, we identified the ubiquitination factor Fbxw7 as an mTOR regulator that oscillated in its expression in a manner opposite from mTOR. Fbxw7 transcription was regulated by the circadian regulator D-site-binding protein. Notably, administration of the mTOR inhibitor everolimus during periods of elevated mTOR improved survival in tumor-bearing mice. Our findings demonstrate that the circadian oscillation of mTOR activity is regulated by circadian clock systems, which influence the antitumor effect of mTOR inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24253377     DOI: 10.1158/0008-5472.CAN-12-3241

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression.

Authors:  Yan Zhou; Rui-hua Zhao; Kuo-fu Tseng; Kun-peng Li; Zhi-gang Lu; Yuan Liu; Kun Han; Zhi-hua Gan; Shu-chen Lin; Hai-yan Hu; Da-liu Min
Journal:  Acta Pharmacol Sin       Date:  2016-02-29       Impact factor: 6.150

Review 2.  Circadian clocks, epigenetics, and cancer.

Authors:  Selma Masri; Kenichiro Kinouchi; Paolo Sassone-Corsi
Journal:  Curr Opin Oncol       Date:  2015-01       Impact factor: 3.645

3.  Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock.

Authors:  Yuan Zhang; Sylvie Giacchetti; Alexandre Parouchev; Eva Hadadi; Xiaomei Li; Robert Dallmann; Helena Xandri-Monje; Lucie Portier; René Adam; Françis Lévi; Sandrine Dulong; Yunhua Chang
Journal:  Cell Cycle       Date:  2018-01-02       Impact factor: 4.534

4.  Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome.

Authors:  Sarah E M Stephenson; Gregory Costain; Laura E R Blok; Michael A Silk; Thanh Binh Nguyen; Xiaomin Dong; Dana E Alhuzaimi; James J Dowling; Susan Walker; Kimberly Amburgey; Robin Z Hayeems; Lance H Rodan; Marc A Schwartz; Jonathan Picker; Sally A Lynch; Aditi Gupta; Kristen J Rasmussen; Lisa A Schimmenti; Eric W Klee; Zhiyv Niu; Katherine E Agre; Ilana Chilton; Wendy K Chung; Anya Revah-Politi; P Y Billie Au; Christopher Griffith; Melissa Racobaldo; Annick Raas-Rothschild; Bruria Ben Zeev; Ortal Barel; Sebastien Moutton; Fanny Morice-Picard; Virginie Carmignac; Jenny Cornaton; Nathalie Marle; Orrin Devinsky; Chandler Stimach; Stephanie Burns Wechsler; Bryan E Hainline; Katie Sapp; Marjolaine Willems; Ange-Line Bruel; Kerith-Rae Dias; Carey-Anne Evans; Tony Roscioli; Rani Sachdev; Suzanna E L Temple; Ying Zhu; Joshua J Baker; Ingrid E Scheffer; Fiona J Gardiner; Amy L Schneider; Alison M Muir; Heather C Mefford; Amy Crunk; Elizabeth M Heise; Francisca Millan; Kristin G Monaghan; Richard Person; Lindsay Rhodes; Sarah Richards; Ingrid M Wentzensen; Benjamin Cogné; Bertrand Isidor; Mathilde Nizon; Marie Vincent; Thomas Besnard; Amelie Piton; Carlo Marcelis; Kohji Kato; Norihisa Koyama; Tomoo Ogi; Elaine Suk-Ying Goh; Christopher Richmond; David J Amor; Jessica O Boyce; Angela T Morgan; Michael S Hildebrand; Antony Kaspi; Melanie Bahlo; Rún Friðriksdóttir; Hildigunnur Katrínardóttir; Patrick Sulem; Kári Stefánsson; Hans Tómas Björnsson; Simone Mandelstam; Manuela Morleo; Milena Mariani; Marcello Scala; Andrea Accogli; Annalaura Torella; Valeria Capra; Mathew Wallis; Sandra Jansen; Quinten Weisfisz; Hugoline de Haan; Simon Sadedin; Sze Chern Lim; Susan M White; David B Ascher; Annette Schenck; Paul J Lockhart; John Christodoulou; Tiong Yang Tan
Journal:  Am J Hum Genet       Date:  2022-04-07       Impact factor: 11.043

Review 5.  Molecular clocks and the human condition: approaching their characterization in human physiology and disease.

Authors:  G A Fitzgerald; G Yang; G K Paschos; X Liang; C Skarke
Journal:  Diabetes Obes Metab       Date:  2015-09       Impact factor: 6.577

Review 6.  Broad targeting of angiogenesis for cancer prevention and therapy.

Authors:  Zongwei Wang; Charlotta Dabrosin; Xin Yin; Mark M Fuster; Alexandra Arreola; W Kimryn Rathmell; Daniele Generali; Ganji P Nagaraju; Bassel El-Rayes; Domenico Ribatti; Yi Charlie Chen; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Somaira Nowsheen; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Bill Helferich; Xujuan Yang; Gunjan Guha; Dipita Bhakta; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Dorota Halicka; Sulma I Mohammed; Asfar S Azmi; Alan Bilsland; W Nicol Keith; Lasse D Jensen
Journal:  Semin Cancer Biol       Date:  2015-01-16       Impact factor: 15.707

Review 7.  Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy.

Authors:  Narin Ozturk; Dilek Ozturk; Ibrahim Halil Kavakli; Alper Okyar
Journal:  Int J Mol Sci       Date:  2017-10-17       Impact factor: 5.923

8.  A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.

Authors:  Hongjuan Zhao; John T Leppert; Donna M Peehl
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

9.  Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.

Authors:  Qing-jun Liu; Hong-liang Shen; Jun Lin; Xiu-hong Xu; Zheng-guo Ji; Xiao Han; Dong-hao Shang; Pei-qian Yang
Journal:  Drug Des Devel Ther       Date:  2016-02-18       Impact factor: 4.162

10.  NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.

Authors:  Hilal S Khalil; Simon P Langdon; Ibrahim H Kankia; James Bown; Yusuf Y Deeni
Journal:  Oxid Med Cell Longev       Date:  2015-12-07       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.